SUTRO BIOPHARMA, INC. Long-Term Debt
SUTRO BIOPHARMA, INC. (STRO) had Long-Term Debt of $0 as of 2023-12-31, per its 10-K filed 2024-03-25.
Discontinued › Balance Sheet › Liabilities › Liabilities, Noncurrent
us-gaap:LongTermDebtNoncurrent · last filed 2024-03-25
- 2023-12-31: Long-term Debt, Excluding Current Maturities $0.00.
- 2022-12-31: Long-term Debt, Excluding Current Maturities $3.77M.
- 2022-09-30: Long-term Debt, Excluding Current Maturities $6.78M.
- 2022-06-30: Long-term Debt, Excluding Current Maturities $9.78M.
| Period end | Long-term Debt, Excluding Current Maturities |
|---|---|
| 2023-12-31 | $0.00 10-K · filed 2024-03-25 |
| 2022-12-31 | $3.77M 10-K · filed 2024-03-25 |
| 2022-09-30 | $6.78M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $9.78M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $12.76M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $15.74M 10-K · filed 2023-03-30 |
| 2021-09-30 | $18.71M 10-Q · filed 2021-11-10 |
| 2021-06-30 | $21.69M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $24.68M 10-Q · filed 2021-05-07 |
| 2020-12-31 | $24.55M 10-K · filed 2022-02-28 |
| 2020-09-30 | $24.41M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $24.28M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $24.16M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $8.88M 10-K · filed 2021-03-18 |
| 2019-09-30 | $5.50M 10-Q · filed 2019-11-08 |
| 2019-06-30 | $7.00M 10-Q · filed 2019-08-14 |
| 2019-03-31 | $8.50M 10-Q · filed 2019-05-15 |
| 2018-12-31 | $10.00M 10-K · filed 2020-03-16 |
| 2018-09-30 | $11.50M 10-Q · filed 2018-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 |